| scholarly article | Q13442814 |
| P2093 | author name string | D Chilov | |
| K Alitalo | |||
| K Pajusola | |||
| A Kaipainen | |||
| V Joukov | |||
| E Kukk | |||
| N Kalkkinen | |||
| O Saksela | |||
| I Lahtinen | |||
| P2860 | cites work | Crystal structure of human platelet-derived growth factor BB | Q24293538 |
| Identification of the KDR tyrosine kinase as a receptor for vascular endothelial cell growth factor | Q24294262 | ||
| cDNA sequence and chromosomal localization of human platelet-derived growth factor A-chain and its expression in tumour cell lines | Q24299707 | ||
| Distinct roles of the receptor tyrosine kinases Tie-1 and Tie-2 in blood vessel formation | Q24316945 | ||
| Biochemical characterization of two isoforms of FLT4, a VEGF receptor-related tyrosine kinase | Q24318336 | ||
| Different signal transduction properties of KDR and Flt1, two receptors for vascular endothelial growth factor | Q24323249 | ||
| The fms-like tyrosine kinase, a receptor for vascular endothelial growth factor | Q24328901 | ||
| Isolation of a human placenta cDNA coding for a protein related to the vascular permeability factor | Q24560244 | ||
| 'Touchdown' PCR to circumvent spurious priming during gene amplification | Q24630793 | ||
| Cleavage of Structural Proteins during the Assembly of the Head of Bacteriophage T4 | Q25938983 | ||
| A new method for predicting signal sequence cleavage sites | Q27861117 | ||
| The FLT4 gene encodes a transmembrane tyrosine kinase related to the vascular endothelial growth factor receptor | Q28115309 | ||
| Placenta growth factor. Potentiation of vascular endothelial growth factor bioactivity, in vitro and in vivo, and high affinity binding to Flt-1 but not to Flk-1/KDR | Q28238949 | ||
| Two alternative mRNAs coding for the angiogenic factor, placenta growth factor (PlGF), are transcribed from a single gene of chromosome 14 | Q28297843 | ||
| Dominant-negative and targeted null mutations in the endothelial receptor tyrosine kinase, tek, reveal a critical role in vasculogenesis of the embryo | Q28586040 | ||
| Role of the Flt-1 receptor tyrosine kinase in regulating the assembly of vascular endothelium | Q28587604 | ||
| Failure of blood-island formation and vasculogenesis in Flk-1-deficient mice | Q28593600 | ||
| High affinity VEGF binding and developmental expression suggest Flk-1 as a major regulator of vasculogenesis and angiogenesis | Q28594191 | ||
| Signalling properties of FLT4, a proteolytically processed receptor tyrosine kinase related to two VEGF receptors | Q28611479 | ||
| Vascular endothelial growth factor is a secreted angiogenic mitogen | Q28646475 | ||
| Angiogenesis in cancer, vascular, rheumatoid and other disease | Q29547165 | ||
| Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid | Q29617640 | ||
| FLT4 receptor tyrosine kinase contains seven immunoglobulin-like loops and is expressed in multiple human tissues and cell lines | Q30984508 | ||
| Long-term culture of capillary endothelial cells | Q34038077 | ||
| Assignment of interchain disulfide bonds in platelet-derived growth factor (PDGF) and evidence for agonist activity of monomeric PDGF | Q34235775 | ||
| Two human FLT4 receptor tyrosine kinase isoforms with distinct carboxy terminal tails are produced by alternative processing of primary transcripts | Q34306819 | ||
| Expression of the fms-like tyrosine kinase 4 gene becomes restricted to lymphatic endothelium during development. | Q34455428 | ||
| The receptor tyrosine kinase TIE is required for integrity and survival of vascular endothelial cells. | Q37625629 | ||
| Endothelial receptor tyrosine kinases involved in angiogenesis. | Q40400431 | ||
| Molecular mechanisms of angiogenesis: fibroblast growth factor signal transduction. | Q40402643 | ||
| Differentiation of endothelium. | Q40447467 | ||
| Structure of platelet-derived growth factor: implications for functional properties | Q40832545 | ||
| Role of VEGF-flt receptor system in normal and tumor angiogenesis. | Q40951691 | ||
| Vascular endothelial growth factor is induced in response to transforming growth factor-beta in fibroblastic and epithelial cells. | Q41481649 | ||
| Glioblastoma growth inhibited in vivo by a dominant-negative Flk-1 mutant | Q41488146 | ||
| Enhanced secretion from insect cells of a foreign protein fused to the honeybee melittin signal peptide | Q41695196 | ||
| The Balbiani ring 3 gene in Chironomus tentans has a diverged repetitive structure split by many introns | Q41840020 | ||
| Balbiani ring 3 in Chironomus tentans encodes a 185-kDa secretory protein which is synthesized throughout the fourth larval instar | Q42633114 | ||
| Identification and structural analysis of the A type receptor for platelet-derived growth factor. Similarities with the B type receptor. | Q45933270 | ||
| Molecular cloning of murine FLT and FLT4. | Q48107458 | ||
| Changes in the vascular extracellular matrix during embryonic vasculogenesis and angiogenesis | Q48117290 | ||
| Covalent dimerization of vascular permeability factor/vascular endothelial growth factor is essential for its biological activity. Evidence from Cys to Ser mutations | Q72372332 | ||
| P433 | issue | 2 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | endothelium | Q111140 |
| Vascular endothelial growth factor C | Q7916457 | ||
| positive regulation of cell population proliferation | Q14633891 | ||
| P304 | page(s) | 290-98 | |
| P577 | publication date | 1996-01-15 | |
| P1433 | published in | The EMBO Journal | Q1278554 |
| P1476 | title | A novel vascular endothelial growth factor, VEGF-C, is a ligand for the Flt4 (VEGFR-3) and KDR (VEGFR-2) receptor tyrosine kinases | |
| P478 | volume | 15 |
| Q40958024 | A Mathematical Model of Lymphangiogenesis in a Zebrafish Embryo |
| Q92698744 | A Novel Role of VEGFC in Cerebral Ischemia With Lung Injury |
| Q45324454 | A Novel Vascular Endothelial Growth Factor Receptor Participates in White Spot Syndrome Virus Infection in Litopenaeus vannamei |
| Q38782636 | A Simple Bioassay for the Evaluation of Vascular Endothelial Growth Factors |
| Q95277500 | A Single-Cell Transcriptional Roadmap of the Mouse and Human Lymph Node Lymphatic Vasculature |
| Q33890319 | A novel vascular endothelial growth factor encoded by Orf virus, VEGF-E, mediates angiogenesis via signalling through VEGFR-2 (KDR) but not VEGFR-1 (Flt-1) receptor tyrosine kinases |
| Q34461897 | A proteomic study of potential VEGF-C-associated proteins in bladder cancer T24 cells |
| Q30537569 | A truncation allele in vascular endothelial growth factor c reveals distinct modes of signaling during lymphatic and vascular development. |
| Q36796299 | Altered expression of endogenous soluble vascular endothelial growth factor receptor-2 is involved in the progression of esophageal squamous cell carcinoma |
| Q33899627 | Alternatively spliced vascular endothelial growth factor receptor-2 is an essential endogenous inhibitor of lymphatic vessel growth. |
| Q36477682 | An antagonistic vascular endothelial growth factor (VEGF) variant inhibits VEGF-stimulated receptor autophosphorylation and proliferation of human endothelial cells |
| Q34071311 | An interstitial hypothesis for breast cancer related lymphoedema |
| Q35366220 | An overview of lymphatic vessels and their emerging role in cardiovascular disease |
| Q41942219 | Angiogenesis and vasculogenesis in treatment of cardiovascular disease. |
| Q96135356 | Angiogenesis in Breast Cancer Progression, Diagnosis, and Treatment |
| Q37139109 | Angiogenesis-related pathways in the pathogenesis of ovarian cancer |
| Q33437576 | Anti-angiogenesis effect of the novel anti-inflammatory and pro-resolving lipid mediators |
| Q33692555 | Anticancer Role of PPARgamma Agonists in Hematological Malignancies Found in the Vasculature, Marrow, and Eyes. |
| Q34112190 | Association of serum vascular endothelial growth factor-C and lymphatic vessel density with lymph node metastasis and prognosis of patients with gastric cancer |
| Q90390278 | Atypical cadherin Fat4 orchestrates lymphatic endothelial cell polarity in response to flow |
| Q54985404 | Biology of Vascular Endothelial Growth Factor C in the Morphogenesis of Lymphatic Vessels. |
| Q37654773 | Biomarkers of angiogenesis and their role in the development of VEGF inhibitors |
| Q34066152 | Blockade of vascular endothelial growth factor receptor-3 signaling inhibits fibroblast growth factor-2-induced lymphangiogenesis in mouse cornea. |
| Q39093915 | Bone marrow micro-environment is a crucial player for myelomagenesis and disease progression. |
| Q26826870 | Brain homeostasis: VEGF receptor 1 and 2-two unequal brothers in mind |
| Q34727910 | CRSBP-1/LYVE-1 ligands disrupt lymphatic intercellular adhesion by inducing tyrosine phosphorylation and internalization of VE-cadherin |
| Q36677718 | Cadherin-17 induces tumorigenesis and lymphatic metastasis in gastric cancer through activation of NFκB signaling pathway |
| Q37362180 | Characterization of lymphangiogenesis in a model of adult skin regeneration. |
| Q37156639 | Circulating lymphangiogenic growth factors in gastrointestinal solid tumors, could they be of any clinical significance? |
| Q36695475 | Clinical implication of expression of vascular endothelial growth factor-C in metastatic lymph nodes of uterine cervical cancers |
| Q36735345 | Clinicopathological Significance of VEGF-C, VEGFR-3 and Cyclooxygenase-2 in Early-Stage Cervical Cancer |
| Q35746804 | Concurrent induction of lymphangiogenesis, angiogenesis, and macrophage recruitment by vascular endothelial growth factor-C in melanoma |
| Q26823757 | Corneal neovascularization and the utility of topical VEGF inhibition: ranibizumab (Lucentis) vs bevacizumab (Avastin) |
| Q36854026 | Correlation of vascular endothelial growth factor-D expression and VEGFR-3-positive vessel density with lymph node metastasis in gastric carcinoma |
| Q37365788 | Cytokine signaling through the novel tyrosine kinase RAFTK in Kaposi's sarcoma cells |
| Q36804671 | Deletion of vascular endothelial growth factor C (VEGF-C) and VEGF-D is not equivalent to VEGF receptor 3 deletion in mouse embryos |
| Q40073882 | Development of the LYVE-1 Gene with An Acidic-amino-acid-rich (AAAR) Domain in Evolution Is Associated with Acquisition of Lymph Nodes and Efficient Adaptive Immunity. |
| Q37551405 | Differential Receptor Binding and Regulatory Mechanisms for the Lymphangiogenic Growth Factors Vascular Endothelial Growth Factor (VEGF)-C and -D. |
| Q34248544 | Differential expression of the angiogenesis growth factors in psoriasis vulgaris |
| Q36493852 | Differential expression of vascular endothelial growth factor A, its receptors VEGFR-1, -2, and -3 and co-receptors neuropilin-1 and -2 does not predict bevacizumab response in human astrocytomas |
| Q36267269 | Differential gene expression of primary cultured lymphatic and blood vascular endothelial cells. |
| Q34597815 | Distinct genetic interactions between multiple Vegf receptors are required for development of different blood vessel types in zebrafish |
| Q37415307 | Dose-dependent response of FGF-2 for lymphangiogenesis |
| Q36503028 | Downregulation of survivin expression exerts antitumoral effects on mouse breast cancer cells in vitro and in vivo. |
| Q42149105 | Effect of CCR7, CXCR4 and VEGF-C on the lymph node metastasis of human pancreatic ductal adenocarcinoma |
| Q79550090 | Effect of HIF-1alpha on VEGF-C induced lymphangiogenesis and lymph nodes metastases of pancreatic cancer |
| Q52726355 | Effect of High VEGF-C mRNA Expression on Achievement of Complete Remission in Adult Acute Myeloid Leukemia. |
| Q36076347 | Effect of hepatoma H22 on lymphatic endothelium in vitro |
| Q33723780 | Effect of inflammatory cytokines on the expression of the vascular endothelial growth factor-C. |
| Q38727572 | Effects of fatty acid synthase inhibitors on lymphatic vessels: an in vitro and in vivo study in a melanoma model |
| Q87010226 | Effects of vascular endothelial growth factor B on proliferation and migration in EA.Hy926 cells |
| Q28829519 | Elevated VEGF-D Modulates Tumor Inflammation and Reduces the Growth of Carcinogen-Induced Skin Tumors |
| Q37341131 | Emerging Role of Sphingosine-1-phosphate in Inflammation, Cancer, and Lymphangiogenesis |
| Q47233157 | Emerging Roles for VEGF-D in Human Disease |
| Q40379734 | Endostatin inhibits lymph node metastasis by a down-regulation of the vascular endothelial growth factor C expression in tumor cells |
| Q36220259 | Endostatin's emerging roles in angiogenesis, lymphangiogenesis, disease, and clinical applications. |
| Q36157482 | Enhanced Mitogenic Activity of Recombinant Human Vascular Endothelial Growth Factor VEGF121 Expressed in E. coli Origami B (DE3) with Molecular Chaperones |
| Q48139522 | Erythropoietin prevents blood brain barrier damage induced by focal cerebral ischemia in mice |
| Q34347218 | Existence of the lymphatic system in the primate corpus luteum |
| Q34989014 | Experimental assessment of pro-lymphangiogenic growth factors in the treatment of post-surgical lymphedema following lymphadenectomy |
| Q35103259 | Expression of lymphangiogenic factors and evidence of intratumoral lymphangiogenesis in pancreatic endocrine tumors |
| Q36542740 | Expression of placenta growth factor in colorectal carcinomas |
| Q42850952 | Expression of the vascular endothelial growth factor C receptor VEGFR-3 in lymphatic endothelium of the skin and in vascular tumors |
| Q55261166 | Expression of vascular endothelial growth factor (VEGF) family members in breast cancer. |
| Q34733388 | Expression of vascular endothelial growth factor C and anti-angiogenesis therapy in endometriosis. |
| Q36502541 | Expression of vascular endothelial growth factor C and chemokine receptor CCR7 in gastric carcinoma and their values in predicting lymph node metastasis. |
| Q34017710 | Expression of vascular endothelial growth factor-C and angiogenesis in esophageal squamous cell carcinoma |
| Q38376244 | Expression of vascular endothelial growth factor-C and vascular endothelial growth factor receptor-3 in esophageal squamous cell carcinoma |
| Q33788147 | Expression of vascular endothelial growth factors A and C in human pancreatic cancer |
| Q64929653 | Expression profiles of VEGF-A, VEGF-D and VEGFR1 are higher in distant metastases than in matched primary high grade epithelial ovarian cancer. |
| Q47368100 | Friends Turned Foes: Angiogenic Growth Factors beyond Angiogenesis |
| Q37134125 | From germline towards somatic mutations in the pathophysiology of vascular anomalies |
| Q38157505 | Gene and protein therapies utilizing VEGF for ALS. |
| Q65000297 | Generalized Lymphatic Anomaly and Gorham-Stout Disease: Overview and Recent Insights. |
| Q35102884 | Generation and characterization of telomerase-transfected human lymphatic endothelial cells with an extended life span |
| Q36021580 | Genetic and hypoxic regulation of angiogenesis in gliomas |
| Q73373512 | Genetic mapping of the vascular endothelial growth factor (Vegf) gene to mouse chromosome 17 |
| Q34362133 | Genomic scan reveals loci under altitude adaptation in Tibetan and Dahe pigs. |
| Q36957480 | GnRH analogues in the prevention of ovarian hyperstimulation syndrome |
| Q90338530 | Hemostasis stimulates lymphangiogenesis through release and activation of VEGFC |
| Q37758600 | Heterogeneity and plasticity of lymphatic endothelial cells |
| Q83069785 | Histopathological predictor for regional lymph node metastasis in gastric cancer |
| Q35788580 | Human herpesvirus-8-transformed endothelial cells have functionally activated vascular endothelial growth factor/vascular endothelial growth factor receptor |
| Q37345218 | Hypoxia-induced factor-1 alpha upregulates vascular endothelial growth factor C to promote lymphangiogenesis and angiogenesis in breast cancer patients |
| Q91812815 | Hypoxia: Overview on Hypoxia-Mediated Mechanisms with a Focus on the Role of HIF Genes |
| Q24604514 | Identification of a c-fos-induced gene that is related to the platelet-derived growth factor/vascular endothelial growth factor family |
| Q30750084 | Immunolocalisation of the VEGF receptors FLT-1, KDR, and FLT-4 in diabetic retinopathy |
| Q42000250 | Impact of exploratory biomarkers on the treatment effect of bevacizumab in metastatic breast cancer |
| Q79603906 | Impact of immunohistochemically identified lymphatic invasion on nodal metastasis in early gastric cancer |
| Q42281477 | Impact of the prolymphangiogenic crosstalk in the tumor microenvironment on lymphatic cancer metastasis. |
| Q37361775 | In vivo angiogenic activity and hypoxia induction of heterodimers of placenta growth factor/vascular endothelial growth factor |
| Q41024413 | Inflammatory biomarkers and spontaneous preterm birth among obese women |
| Q33832620 | Inhibition of tumor growth and metastasis by targeting tumor-associated angiogenesis with antagonists to the receptors of vascular endothelial growth factor |
| Q92002622 | Integrating Biological Advances Into the Clinical Management of Breast Cancer Related Lymphedema |
| Q35810928 | Integrins and their extracellular matrix ligands in lymphangiogenesis and lymph node metastasis |
| Q37781426 | Interaction between the extracellular matrix and lymphatics: consequences for lymphangiogenesis and lymphatic function |
| Q34340057 | Interleukin-1β expression is required for lysophosphatidic Acid-induced lymphangiogenesis in human umbilical vein endothelial cells |
| Q35261533 | Intramembrane binding of VE-cadherin to VEGFR2 and VEGFR3 assembles the endothelial mechanosensory complex |
| Q24291630 | Isolated lymphatic endothelial cells transduce growth, survival and migratory signals via the VEGF-C/D receptor VEGFR-3 |
| Q64005186 | KLK3/PSA and cathepsin D activate VEGF-C and VEGF-D. |
| Q33897202 | Kinase inhibitors in cancer therapy: a look ahead |
| Q83226383 | Late developing cardiac lymphatic vasculature supports adult zebrafish heart function and regeneration |
| Q37226530 | Leptin's Pro-Angiogenic Signature in Breast Cancer |
| Q36766439 | Ligand-dependent development of the endothelial and hemopoietic lineages from embryonic mesodermal cells expressing vascular endothelial growth factor receptor 2. |
| Q35587460 | Localisation of members of the vascular endothelial growth factor (VEGF) family and their receptors in human atherosclerotic arteries |
| Q36137692 | Lymphangiogenesis and cancer |
| Q84190566 | Lymphangiogenesis and cancer metastasis |
| Q35575870 | Lymphangiogenesis and hemangiogenesis: potential targets for therapy |
| Q36515990 | Lymphangiogenesis and lymph node metastasis in breast cancer |
| Q38190359 | Lymphangiogenesis and lymphatic vessel remodelling in cancer |
| Q47744569 | Lymphangiogenesis guidance by paracrine and pericellular factors |
| Q50273163 | Lymphangiogenesis in rat asthma model |
| Q28742322 | Lymphangiogenesis is required for pancreatic islet inflammation and diabetes |
| Q88886615 | Lymphangiogenesis, lymphatic systemomics, and cancer: context, advances and unanswered questions |
| Q33994917 | Lymphangiogenesis-independent resolution of experimental edema |
| Q24672687 | Lymphatic endothelium: morphological, molecular and functional properties |
| Q30481281 | Lymphatic vessel density and function in experimental bladder cancer |
| Q34372169 | Lymphatic vessels as targets of tumor therapy? |
| Q35805972 | Lymphatics at the crossroads of angiogenesis and lymphangiogenesis |
| Q90480738 | Lymphedema in survivors of breast cancer |
| Q33555154 | Lymphovascular and neural regulation of metastasis: shared tumour signalling pathways and novel therapeutic approaches |
| Q64114248 | Lysyl Oxidase-Like Protein 2 Promotes Tumor Lymphangiogenesis and Lymph Node Metastasis in Breast Cancer |
| Q48112689 | Macropinocytosis of Bevacizumab by Glioblastoma Cells in the Perivascular Niche Affects their Survival |
| Q38066006 | Mammary cancer gene therapy targeting lymphangiogenesis: VEGF-C siRNA and soluble VEGF receptor-2, a splicing variant |
| Q34802847 | Metastasis via Peritumoral Lymphatic Dilation in Oral Squamous Cell Carcinoma |
| Q36611431 | Migration-promoting role of VEGF-C and VEGF-C binding receptors in human breast cancer cells. |
| Q39618556 | Modulating metastasis by a lymphangiogenic switch in prostate cancer |
| Q91796775 | Molecular Signature of Prospero Homeobox 1 (PROX1) in Follicular Thyroid Carcinoma Cells |
| Q34566028 | Molecular and functional diversity of vascular endothelial growth factors |
| Q34415420 | Molecular characterization of lymphatic endothelial cells. |
| Q36729562 | Molecular heterogeneity of glioblastomas: does location matter? |
| Q80416374 | Molecular mechanisms of lymphangiogenesis |
| Q37947968 | Molecular pathways of lymphangiogenesis and lymph node metastasis in head and neck cancer |
| Q39144827 | Myeloid cells pave the way for lymphatic system development and maintenance |
| Q39736018 | Neuroblastoma progression correlates with downregulation of the lymphangiogenesis inhibitor sVEGFR-2. |
| Q33616451 | Neuropilin-2 mediates VEGF-C-induced lymphatic sprouting together with VEGFR3. |
| Q33530399 | Non-peptide small molecule regulators of lymphangiogenesis |
| Q84704956 | Novel antiangiogenic therapies against advanced hepatocellular carcinoma (HCC) |
| Q35791588 | Novel expression of vascular endothelial growth factor receptor (VEGFR)-3 and VEGF-C on corneal dendritic cells |
| Q34218202 | Obesity-associated insulin resistance is correlated to adipose tissue vascular endothelial growth factors and metalloproteinase levels |
| Q83853939 | Of mice and men; the translational physiology of a genetic form of lymphoedema |
| Q39035373 | Overexpression of AKIP1 promotes angiogenesis and lymphangiogenesis in human esophageal squamous cell carcinoma |
| Q91870991 | Overexpression of VEGF-C and MMP-9 predicts poor prognosis in Kazakh patients with esophageal squamous cell carcinoma |
| Q33859145 | Overexpression of both platelet-derived growth factor-BB and vascular endothelial growth factor-C and its association with lymphangiogenesis in primary human non-small cell lung cancer |
| Q79914651 | Overexpression of vascular endothelial growth factor-C correlates with lymph node micrometastasis in submucosal esophageal cancer |
| Q38287296 | PEG-Immobilized Keratin for Protein Drug Sequestration and pH-Mediated Delivery |
| Q37171889 | Pathogenesis of lymphangiomas |
| Q36742274 | Pathophysiology of tumor neovascularization |
| Q34406774 | Periostin directly and indirectly promotes tumor lymphangiogenesis of head and neck cancer |
| Q77995177 | Peripheral blood mononuclear cells from patients with rheumatoid arthritis spontaneously secrete vascular endothelial growth factor (VEGF): specific up-regulation by tumour necrosis factor-alpha (TNF-alpha) in synovial fluid |
| Q27005573 | Pharmacological aspects of Vipera xantina palestinae venom |
| Q36382124 | Pharmacological targeting of VEGFR signaling with axitinib inhibits Tsc2-null lesion growth in the mouse model of lymphangioleiomyomatosis |
| Q73293875 | Placenta growth factor (PlGF) induces vascular endothelial growth factor (VEGF) secretion from mononuclear cells and is co-expressed with VEGF in synovial fluid |
| Q24672582 | Plasmin activates the lymphangiogenic growth factors VEGF-C and VEGF-D |
| Q64259309 | Possible biomarkers for predicting lymph node metastasis of esophageal squamous cell carcinoma: a review |
| Q36851512 | Potential therapeutic strategies for lymphatic metastasis |
| Q35859226 | Primary Tumor-Secreted Lymphangiogenic Factors Induce Pre-Metastatic Lymphvascular Niche Formation at Sentinel Lymph Nodes in Oral Squamous Cell Carcinoma |
| Q35829688 | Production of experimental malignant pleural effusions is dependent on invasion of the pleura and expression of vascular endothelial growth factor/vascular permeability factor by human lung cancer cells |
| Q36064738 | Profiling Analysis of Histone Modifications and Gene Expression in Lewis Lung Carcinoma Murine Cells Resistant to Anti-VEGF Treatment |
| Q80934411 | Prognostic significance of VEGF immunohistochemical expression and tumor angiogenesis in head and neck squamous cell carcinoma |
| Q47581817 | Prognostic significance of vascular endothelial growth factor immunohistochemical expression in gastric cancer: a meta-analysis |
| Q37407354 | Promotion of metastasis of thyroid cancer cells via NRP-2-mediated induction |
| Q36951786 | Proteolytic activation defines distinct lymphangiogenic mechanisms for VEGFC and VEGFD. |
| Q24532314 | Proteolytic processing regulates receptor specificity and activity of VEGF-C. |
| Q41858670 | Purification and refolding of vascular endothelial growth factor-B. |
| Q41791347 | Quantification and cell-to-cell variation of vascular endothelial growth factor receptors. |
| Q32184965 | RNAi-mediated gene silencing of vascular endothelial growth factor C suppresses growth and induces apoptosis in mouse breast cancer in vitro and in vivo |
| Q35928217 | Radiogenic lymphangiogenesis in the skin |
| Q35062979 | Regulating the angiogenic balance in tissues |
| Q34774011 | Regulation of microvascular permeability by vascular endothelial growth factors |
| Q28068654 | Relationship between hypoxia and response to antiangiogenic therapy in metastatic colorectal cancer |
| Q36292232 | Release of the angiogenic cytokine vascular endothelial growth factor (VEGF) from platelets: significance for VEGF measurements and cancer biology. |
| Q98291421 | Resistance to Anti-angiogenic Therapies: A Mechanism Depending on the Time of Exposure to the Drugs |
| Q28364512 | Reversal of experimental diabetic neuropathy by VEGF gene transfer |
| Q35181953 | Role of VEGF in kidney development, microvascular maintenance and pathophysiology of renal disease |
| Q40358278 | Role of VEGF-C and VEGF-D in lymphangiogenesis in gastric cancer |
| Q38229747 | Role of lymphatic vasculature in regional and distant metastases |
| Q35851527 | Role of shear-stress-induced VEGF expression in endothelial cell survival |
| Q34017124 | Role of sphingosine kinase-1 in paracrine/transcellular angiogenesis and lymphangiogenesis in vitro. |
| Q37738074 | Role of tumor microenvironment in tumorigenesis |
| Q35300661 | Role of vascular permeability factor/vascular endothelial growth factor in eye disease |
| Q36032941 | Roles of neuropilins in neuronal development, angiogenesis, and cancers |
| Q33616384 | Roles of vascular endothelial growth factor in amyotrophic lateral sclerosis |
| Q36679422 | Sentinel node and mechanism of lymphatic metastasis |
| Q34266010 | Serum angiopoietin-2 and soluble VEGFR-2 levels predict malignancy of ovarian neoplasm and poor prognosis in epithelial ovarian cancer |
| Q57788704 | Serum vascular endothelial growth factor-C levels predict lymph node metastasis and prognosis of patients with gallbladder cancer |
| Q33267276 | Short and long-term effects of hVEGF-A(165) in Cre-activated transgenic mice |
| Q39165264 | Signaling for lymphangiogenesis via VEGFR-3 is required for the early events of metastasis. |
| Q39714957 | Signalling via vascular endothelial growth factor receptor-3 is sufficient for lymphangiogenesis in transgenic mice |
| Q34003819 | Slit2N and Robo4 regulate lymphangiogenesis through the VEGF-C/VEGFR-3 pathway |
| Q35501362 | Small peptides derived from somatotropin domain-containing proteins inhibit blood and lymphatic endothelial cell proliferation, migration, adhesion and tube formation |
| Q34706749 | Soluble VEGFR-2: an antilymphangiogenic variant of VEGF receptors. |
| Q48488963 | Spatial expression of VEGF-A in human glioma |
| Q36835075 | Sphingosine-1-phosphate promotes lymphangiogenesis by stimulating S1P1/Gi/PLC/Ca2+ signaling pathways |
| Q34369602 | Stromal impact on tumor growth and lymphangiogenesis in human carcinoma xenografts |
| Q27659686 | Structural determinants of growth factor binding and specificity by VEGF receptor 2 |
| Q33565805 | Suppression of prostate cancer nodal and systemic metastasis by blockade of the lymphangiogenic axis |
| Q38241190 | Targeting angiogenesis and tumor microenvironment in metastatic colorectal cancer: role of aflibercept. |
| Q36461582 | Targeting lymphangiogenesis to prevent tumour metastasis |
| Q34078275 | Targeting lymphatic vessel functions through tyrosine kinases |
| Q35060325 | Targeting receptor tyrosine kinase on lymphatic endothelial cells for the therapy of colon cancer lymph node metastasis |
| Q46407140 | Ten years of anti-vascular endothelial growth factor therapy |
| Q57793720 | The Meningeal Lymphatic System: A New Player in Neurophysiology |
| Q92713967 | The Role of VEGF and TNF-Alpha on Epithelialization of Diabetic Foot Ulcers after Hyperbaric Oxygen Therapy |
| Q37516448 | The Role of the Tumor Vasculature in the Host Immune Response: Implications for Therapeutic Strategies Targeting the Tumor Microenvironment |
| Q37354128 | The VEGF signaling pathway in cancer: the road ahead |
| Q46680605 | The chronic effect of vascular endothelial growth factor on individually perfused frog mesenteric microvessels |
| Q36339264 | The connection between lymphangiogenic signalling and prostaglandin biology: a missing link in the metastatic pathway. |
| Q39447216 | The effects of vascular endothelial growth factor C knockdown in esophageal squamous cell carcinoma |
| Q33737146 | The endogenous soluble VEGF receptor-2 isoform suppresses lymph node metastasis in a mouse immunocompetent mammary cancer model |
| Q36623444 | The expression of vascular endothelial growth factor C and its receptors in non-small cell lung cancer |
| Q38861930 | The gain-of-function GLI1 transcription factor TGLI1 enhances expression of VEGF-C and TEM7 to promote glioblastoma angiogenesis |
| Q38689578 | The lymphatic system and pancreatic cancer |
| Q37071029 | The non-canonical role of vascular endothelial growth factor-C axis in cancer progression |
| Q39705581 | The relationship between peritumoral brain edema and the expression of vascular endothelial growth factor and its receptors in intracranial meningiomas |
| Q37192740 | The role of platelet-derived growth factor in the pathogenesis of sinonasal polyps: immunohistochemical assessment in epithelial, subepithelial and deep layers of the mucosa |
| Q36241051 | The role of sphingosine-1-phosphate in breast cancer tumor-induced lymphangiogenesis. |
| Q36589860 | The role of the VEGF-C/VEGFRs axis in tumor progression and therapy |
| Q41077200 | The second immunoglobulin-like domain of the VEGF tyrosine kinase receptor Flt-1 determines ligand binding and may initiate a signal transduction cascade |
| Q28208308 | The secretory proprotein convertases furin, PC5, and PC7 activate VEGF-C to induce tumorigenesis |
| Q35949638 | Therapeutic myocardial angiogenesis with vascular endothelial growth factors |
| Q42129574 | Topical bFGF Improves Secondary Lymphedema through Lymphangiogenesis in a Rat Tail Model |
| Q90194802 | Trends and Challenges in Tumor Anti-Angiogenic Therapies |
| Q36244418 | Tumor angiogenesis and molecular target therapy in ovarian carcinomas |
| Q35713318 | Tumor necrosis factor-α promotes the lymphangiogenesis of gallbladder carcinoma through nuclear factor-κB-mediated upregulation of vascular endothelial growth factor-C. |
| Q24669710 | Tumor-associated macrophages express lymphatic endothelial growth factors and are related to peritumoral lymphangiogenesis |
| Q84074740 | Tumor-derived VEGF-C, but not VEGF-D, promotes sentinel lymph node lymphangiogenesis prior to metastasis in breast cancer patients |
| Q36468879 | Tumor-induced lymphangiogenesis in cervical lymph nodes in oral melanoma-bearing mice |
| Q35750191 | Tumor-induced sentinel lymph node lymphangiogenesis and increased lymph flow precede melanoma metastasis |
| Q35895234 | Tying the knot: the cystine signature and molecular-recognition processes of the vascular endothelial growth factor family of angiogenic cytokines. |
| Q52309706 | VEGF (Vascular Endothelial Growth Factor) and Fibrotic Lung Disease. |
| Q36641154 | VEGF and VEGF type C play an important role in angiogenesis and lymphangiogenesis in human malignant mesothelioma tumours. |
| Q34178821 | VEGF in brain tumors |
| Q42049314 | VEGF induces cardiovascular malformation and embryonic lethality |
| Q42353193 | VEGF-A, VEGF-C, and VEGF-D in colorectal cancer progression |
| Q64975690 | VEGF-C and Mortality in Patients With Suspected or Known Coronary Artery Disease. |
| Q39741051 | VEGF-C gene therapy augments postnatal lymphangiogenesis and ameliorates secondary lymphedema. |
| Q37035753 | VEGF-C induced angiogenesis preferentially occurs at a distance from lymphangiogenesis. |
| Q35616124 | VEGF-C-induced lymphangiogenesis in sentinel lymph nodes promotes tumor metastasis to distant sites |
| Q37352264 | VEGF-D promotes pulmonary oedema in hyperoxic acute lung injury |
| Q36901201 | VEGF-c expression in an in vivo model of orthotopic endometrial cancer and retroperitoneal lymph node metastasis |
| Q35786920 | VEGFR-3 and its ligand VEGF-C are associated with angiogenesis in breast cancer |
| Q51097984 | VEGFR3 Modulates Vascular Permeability by Controlling VEGF/VEGFR2 Signaling. |
| Q42455878 | Variations in transfection efficiency of VEGF165 and VEGF121-cDNA: its effects on proliferation and migration of human endothelial cells |
| Q35723904 | Vasa vasorum in atherosclerosis and clinical significance |
| Q35065442 | Vascular endothelial growth factor (VEGF)-like protein from orf virus NZ2 binds to VEGFR2 and neuropilin-1 |
| Q28506172 | Vascular endothelial growth factor A (VEGF-A) is involved in guidance of VEGF receptor-positive cells to the anterior portion of early embryos |
| Q24679724 | Vascular endothelial growth factor B (VEGF-B) binds to VEGF receptor-1 and regulates plasminogen activator activity in endothelial cells |
| Q36734917 | Vascular endothelial growth factor C induces angiogenesis in vivo. |
| Q36439514 | Vascular endothelial growth factor C is an indicator of lymph node metastasis in thoracic esophageal squamous cellcarcinomas and its role in long-term survival after surgery |
| Q30981990 | Vascular endothelial growth factor C promotes cervical cancer metastasis via up-regulation and activation of RhoA/ROCK-2/moesin cascade. |
| Q24321792 | Vascular endothelial growth factor D (VEGF-D) is a ligand for the tyrosine kinases VEGF receptor 2 (Flk1) and VEGF receptor 3 (Flt4) |
| Q28237748 | Vascular endothelial growth factor D is dispensable for development of the lymphatic system |
| Q35781900 | Vascular endothelial growth factor and angiopoietin are required for prostate regeneration |
| Q38303537 | Vascular endothelial growth factor family members are differentially regulated by c-erbB signaling in head and neck squamous carcinoma cells. |
| Q42718493 | Vascular endothelial growth factor receptor 3 directly regulates murine neurogenesis |
| Q34321539 | Vascular endothelial growth factor receptor-3 directly interacts with phosphatidylinositol 3-kinase to regulate lymphangiogenesis. |
| Q35810121 | Vascular endothelial growth factor receptor-3 in lymphangiogenesis in wound healing |
| Q33834038 | Vascular endothelial growth factor-B gene transfer exacerbates retinal and choroidal neovascularization and vasopermeability without promoting inflammation. |
| Q42850939 | Vascular endothelial growth factor-C (VEGF-C/VEGF-2) promotes angiogenesis in the setting of tissue ischemia |
| Q42082279 | Vascular endothelial growth factor-C and its receptor VEGFR-3 in the nasal mucosa and in nasopharyngeal tumors |
| Q84510963 | Vascular endothelial growth factor-C and its receptor type-3 expressed in acute lymphocytic leukemia cases with t(1;19) |
| Q42280089 | Vascular endothelial growth factor-C expression in human prostatic carcinoma and its relationship to lymph node metastasis |
| Q36288143 | Vascular endothelial growth factor-C induces lymphangitic carcinomatosis, an extremely aggressive form of lung metastases |
| Q39664069 | Vascular endothelial growth factor-C promotes the growth and invasion of gallbladder cancer via an autocrine mechanism |
| Q28200101 | Vascular endothelial growth factor-C-mediated lymphangiogenesis promotes tumour metastasis |
| Q35836386 | Vascular endothelial growth factor-D is a key molecule that enhances lymphatic metastasis of soft tissue sarcomas |
| Q24656802 | Vascular endothelial growth factor-D is an independent prognostic factor in epithelial ovarian carcinoma |
| Q35187933 | Vascular endothelial growth factors C and D and lymphangiogenesis in gastrointestinal tract malignancy. |
| Q35753219 | Vascular endothelial growth factors VEGF-B and VEGF-C are expressed in human tumors |
| Q33954958 | Vascular endothelial growth factors and vascular permeability |
| Q35221926 | When it comes to blocking lymphatics, it is all a question of time |
| Q54350590 | [Thymosin beta 10 prompted the VEGF-C expression in lung cancer cell]. |
| Q53930051 | [Vascular endothelial factor (VEGF): therapeutic angiogenesis and vasculogenesis in the treatment of cardiovascular disease] |
| Q36429702 | c-fos-induced growth factor/vascular endothelial growth factor D induces angiogenesis in vivo and in vitro. |
| Q35557027 | miR-101 suppresses vascular endothelial growth factor C that inhibits migration and invasion and enhances cisplatin chemosensitivity of bladder cancer cells |
| Q36244123 | siRNA-mediated knockdown of VEGF-A, VEGF-C and VEGFR-3 suppresses the growth and metastasis of mouse bladder carcinoma in vivo |
Search more.